~~<i id='5A487B8BD9'><strike id='5A487B8BD9'><tt id='5A487B8BD9'><pre id='5A487B8BD9'></pre></tt></strike></i>~~

Home» comprehensive» hotspot

hotspot

author：explore 2025-09-28 04:55:09 Page View：3

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’
Next article： In Memoriam: Notable people who died in 2023

explore

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

Ambulance rides for just $100? Advisers want major billing fixes

AdobeApanelofgovernmentadvisersfinallyhasendorsedideasforCongresstosolvetheparticularlythornyproblem

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

MoonLake credibility takes another hit with mid

MollyFerguson/STATMoonLakeImmunotherapeutics,aSwissbiotech,wasburiedMondayunderanavalancheofitsownda